NCT02323191View on ClinicalTrials.gov

A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

221

Participants

Timeline

Start Date

January 19, 2015

Primary Completion Date

August 21, 2020

Study Completion Date

August 21, 2020

Conditions
Solid Cancers
Interventions
DRUG

Atezolizumab

Participants will receive atezolizumab intravenously at a fixed dose of 1200 milligram (mg) q3w.

DRUG

Emactuzumab

Participants will receive emactuzumab intravenously in ascending dose levels with a starting dose of 500 mg.

Trial Locations (12)

1200

Cliniques Universitaires St-Luc, Brussels

10065

Memorial Sloan-Kettering Cancer Center Breast & Imaging Center, New York

28050

Centro Integral Oncológico Clara Campal Ensayos Clínicos START, Madrid

31008

Clinica Universitaria de Navarra; Servicio de Oncologia, Pamplona

31059

Institut Claudius Regaud; Departement Oncologie Medicale, Toulouse

69373

Centre Leon Berard; Departement Oncologie Medicale, Lyon

94805

Institut Gustave Roussy; Departement Oncologie Medicale, Villejuif

06520

Yale Cancer Center; Medical Oncology, New Haven

02114

Massachusetts General Hospital., Boston

02215

Beth Israel Deaconess Medical Center, Boston

Unknown

Dana Farber - Harvard, Boston

08003

Hospital del Mar; Servicio de Oncologia, Barcelona

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02323191 - A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter